US6518263B1 - Imidazo[4,5-b]pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum - Google Patents
Imidazo[4,5-b]pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum Download PDFInfo
- Publication number
- US6518263B1 US6518263B1 US09/856,712 US85671201A US6518263B1 US 6518263 B1 US6518263 B1 US 6518263B1 US 85671201 A US85671201 A US 85671201A US 6518263 B1 US6518263 B1 US 6518263B1
- Authority
- US
- United States
- Prior art keywords
- compound
- mixture
- abq
- nmr
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 [1*]C1=NC(C(=NC)C(=O)NC2C(=O)N3C(C(=O)[O-])=C(C[N+]4=CC=CC5=C4N=C([5*])N5[4*])CSC23)=*S1.[3*]C Chemical compound [1*]C1=NC(C(=NC)C(=O)NC2C(=O)N3C(C(=O)[O-])=C(C[N+]4=CC=CC5=C4N=C([5*])N5[4*])CSC23)=*S1.[3*]C 0.000 description 27
- PFVRZMZTRNQUNS-UHFFFAOYSA-N CC1CCN(C=N)C1 Chemical compound CC1CCN(C=N)C1 PFVRZMZTRNQUNS-UHFFFAOYSA-N 0.000 description 2
- HTHMVKNHGOVITA-UHFFFAOYSA-N CC1CNC1 Chemical compound CC1CNC1 HTHMVKNHGOVITA-UHFFFAOYSA-N 0.000 description 2
- VJEAYXSNKRHHOO-UHFFFAOYSA-N BC.CC(C)(C)OC(=O)NCCC=O.CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2.NC1=C(NC=O)N=CC=C1 Chemical compound BC.CC(C)(C)OC(=O)NCCC=O.CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2.NC1=C(NC=O)N=CC=C1 VJEAYXSNKRHHOO-UHFFFAOYSA-N 0.000 description 1
- IBDYEYNVKMGDAH-UHFFFAOYSA-N BC.CCN(CCC=O)C(=O)OC(C)(C)C.CCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.NC1=C(NC=O)N=CC=C1 Chemical compound BC.CCN(CCC=O)C(=O)OC(C)(C)C.CCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.NC1=C(NC=O)N=CC=C1 IBDYEYNVKMGDAH-UHFFFAOYSA-N 0.000 description 1
- NKKQRSZLKCOVFI-UHFFFAOYSA-N BC.CN(CCC=O)C(=O)OC(C)(C)C.CN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.NC1=C(NC=O)N=CC=C1 Chemical compound BC.CN(CCC=O)C(=O)OC(C)(C)C.CN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.NC1=C(NC=O)N=CC=C1 NKKQRSZLKCOVFI-UHFFFAOYSA-N 0.000 description 1
- KZJLPLDWJFRYKE-UHFFFAOYSA-N BC.CN(CCC=O)C(=O)OC(C)(C)C.CN(CCCNC1=C(N)N=CC=C1)C(=O)OC(C)(C)C.NC1=C(N)N=CC=C1 Chemical compound BC.CN(CCC=O)C(=O)OC(C)(C)C.CN(CCCNC1=C(N)N=CC=C1)C(=O)OC(C)(C)C.NC1=C(N)N=CC=C1 KZJLPLDWJFRYKE-UHFFFAOYSA-N 0.000 description 1
- QVCOUOJXLXLBTF-SXMBIPSUSA-N BN(CCCN(C)C(=O)OC(C)(C)C)C1=C(/N=C/CCCCCN(C)C)N=CC=C1.CCC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound BN(CCCN(C)C(=O)OC(C)(C)C)C1=C(/N=C/CCCCCN(C)C)N=CC=C1.CCC(C1=CC=CC=C1)C1=CC=CC=C1 QVCOUOJXLXLBTF-SXMBIPSUSA-N 0.000 description 1
- MXNMOFWFEJSABT-VNAFTJRNSA-O BN(CCCN(C)C(=O)OC(C)(C)C)C1=C(N=CN(C)C)[N+](CC2=C(C(=O)OCC3=CC=C(OC)C=C3)N3C(=O)C(NC(=O)/C(=N\OCF)C4=NSC(N)=N4)C3SC2)=CC=C1.[I-] Chemical compound BN(CCCN(C)C(=O)OC(C)(C)C)C1=C(N=CN(C)C)[N+](CC2=C(C(=O)OCC3=CC=C(OC)C=C3)N3C(=O)C(NC(=O)/C(=N\OCF)C4=NSC(N)=N4)C3SC2)=CC=C1.[I-] MXNMOFWFEJSABT-VNAFTJRNSA-O 0.000 description 1
- ZOSZYMGOQZYAQU-QRYVVQSXSA-N C.C.C.C.C.C1=CC2=C(N=C1)N=CN2.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2C=CC=N3)C1.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2N=CC=C3)C1.CC(C)(C)OC(=O)N1CC[C@@H](OS(C)(=O)=O)C1 Chemical compound C.C.C.C.C.C1=CC2=C(N=C1)N=CN2.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2C=CC=N3)C1.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2N=CC=C3)C1.CC(C)(C)OC(=O)N1CC[C@@H](OS(C)(=O)=O)C1 ZOSZYMGOQZYAQU-QRYVVQSXSA-N 0.000 description 1
- AXYXCJAAWAORAT-UHFFFAOYSA-N C.C.C.C.C1=CC2=C(N=C1)N=CN2.CCN1C=NC2=C1C=CC=N2.CCN1C=NC2=C1N=CC=C2 Chemical compound C.C.C.C.C1=CC2=C(N=C1)N=CN2.CCN1C=NC2=C1C=CC=N2.CCN1C=NC2=C1N=CC=C2 AXYXCJAAWAORAT-UHFFFAOYSA-N 0.000 description 1
- SFTWQWBJMNFHRL-UHFFFAOYSA-N C.C.C.C.C1=CC2=C(N=C1)N=CN2.CN1C=NC2=C1C=CC=N2.CN1C=NC2=C1N=CC=C2 Chemical compound C.C.C.C.C1=CC2=C(N=C1)N=CN2.CN1C=NC2=C1C=CC=N2.CN1C=NC2=C1N=CC=C2 SFTWQWBJMNFHRL-UHFFFAOYSA-N 0.000 description 1
- QHSHLUHTYRVFAA-QVJBSGFVSA-N C.C.C.C[C@@H]1CCNC1 Chemical compound C.C.C.C[C@@H]1CCNC1 QHSHLUHTYRVFAA-QVJBSGFVSA-N 0.000 description 1
- LQRWGDOQUPZPJV-UHFFFAOYSA-N C.C.C1=CC2=C(N=C1)N=CN2.CC(C)(C)OC(=O)N1C=NC2=C1C=CC=N2 Chemical compound C.C.C1=CC2=C(N=C1)N=CN2.CC(C)(C)OC(=O)N1C=NC2=C1C=CC=N2 LQRWGDOQUPZPJV-UHFFFAOYSA-N 0.000 description 1
- RZQHKOVJNORPCT-UHFFFAOYSA-N C.C1=CC2=C(N=C1)N=CN2.C1=CC=C(CN2C=NC3=C2C=CC=N3)N=C1.C1=CC=C(CN2C=NC3=C2N=CC=C3)N=C1.ClCC1=CC=CC=N1 Chemical compound C.C1=CC2=C(N=C1)N=CN2.C1=CC=C(CN2C=NC3=C2C=CC=N3)N=C1.C1=CC=C(CN2C=NC3=C2N=CC=C3)N=C1.ClCC1=CC=CC=N1 RZQHKOVJNORPCT-UHFFFAOYSA-N 0.000 description 1
- OTKATFYSCLIUOS-UHFFFAOYSA-N C.CC(C)(C)OC(=O)N1CC(CN2C=NC3=C2C=CC=N3)C1.CC(C)(C)OC(=O)N1CC(CN2C=NC3=C2N=CC=C3)C1.CC(C)(C)OC(=O)N1CC(COS(C)(=O)=O)C1 Chemical compound C.CC(C)(C)OC(=O)N1CC(CN2C=NC3=C2C=CC=N3)C1.CC(C)(C)OC(=O)N1CC(CN2C=NC3=C2N=CC=C3)C1.CC(C)(C)OC(=O)N1CC(COS(C)(=O)=O)C1 OTKATFYSCLIUOS-UHFFFAOYSA-N 0.000 description 1
- MUCIABNNMKVPBF-UHFFFAOYSA-N C.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2C=CC=N3)CC1.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2N=CC=C3)CC1.CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)CC1 Chemical compound C.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2C=CC=N3)CC1.CC(C)(C)OC(=O)N1CCC(N2C=NC3=C2N=CC=C3)CC1.CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)CC1 MUCIABNNMKVPBF-UHFFFAOYSA-N 0.000 description 1
- ALTPGTDZOAEQNU-UHFFFAOYSA-N C.CC(C)(C)OC(=O)NC(CCCN)C(N)=O.CC(C)(C)OC(=O)NC(CCCNC(=O)CN1C=NC2N=CC=CC21)C(N)=O Chemical compound C.CC(C)(C)OC(=O)NC(CCCN)C(N)=O.CC(C)(C)OC(=O)NC(CCCNC(=O)CN1C=NC2N=CC=CC21)C(N)=O ALTPGTDZOAEQNU-UHFFFAOYSA-N 0.000 description 1
- LCEFAFBXVZPCHJ-UHFFFAOYSA-N C.CC(C)(C)OC(=O)NCCCCN1C=NC2=C1C=CC=N2.CC(C)(C)OC(=O)NCCCCN1C=NC2=C1N=CC=C2.CCCCCNC(=O)OC(C)(C)C Chemical compound C.CC(C)(C)OC(=O)NCCCCN1C=NC2=C1C=CC=N2.CC(C)(C)OC(=O)NCCCCN1C=NC2=C1N=CC=C2.CCCCCNC(=O)OC(C)(C)C LCEFAFBXVZPCHJ-UHFFFAOYSA-N 0.000 description 1
- AGJHVOZXUZLSNZ-UHFFFAOYSA-N C.CC(C)(C)OC(=O)NCCN1C=NC2=C1C=CC=N2.CC(C)(C)OC(=O)NCCN1C=NC2=C1N=CC=C2.CCCNC(=O)OC(C)(C)C Chemical compound C.CC(C)(C)OC(=O)NCCN1C=NC2=C1C=CC=N2.CC(C)(C)OC(=O)NCCN1C=NC2=C1N=CC=C2.CCCNC(=O)OC(C)(C)C AGJHVOZXUZLSNZ-UHFFFAOYSA-N 0.000 description 1
- ONXVHUBSLFSHRA-UHFFFAOYSA-N C.CC(CCN1C=NC2=C1C=CC=N2)CNC(=O)OC(C)(C)C.CC(CCN1C=NC2=C1N=CC=C2)CNC(=O)OC(C)(C)C.CC(CCOS(C)(=O)=O)CNC(=O)OC(C)(C)C Chemical compound C.CC(CCN1C=NC2=C1C=CC=N2)CNC(=O)OC(C)(C)C.CC(CCN1C=NC2=C1N=CC=C2)CNC(=O)OC(C)(C)C.CC(CCOS(C)(=O)=O)CNC(=O)OC(C)(C)C ONXVHUBSLFSHRA-UHFFFAOYSA-N 0.000 description 1
- SHUXMDXUTQKLRG-UHFFFAOYSA-N C.CCC(CN1C=NC2=C1C=CC=N2)NC(=O)OC(C)(C)C.CCC(CN1C=NC2=C1N=CC=C2)NC(=O)OC(C)(C)C.CCC(COS(C)(=O)=O)NC(=O)OC(C)(C)C Chemical compound C.CCC(CN1C=NC2=C1C=CC=N2)NC(=O)OC(C)(C)C.CCC(CN1C=NC2=C1N=CC=C2)NC(=O)OC(C)(C)C.CCC(COS(C)(=O)=O)NC(=O)OC(C)(C)C SHUXMDXUTQKLRG-UHFFFAOYSA-N 0.000 description 1
- SNZWLSICAWEWEJ-LDAXPMKESA-O C.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)N(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)N(C)C)CSC12)C1=NSC(N)=N1.[I-] Chemical compound C.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)N(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)N(C)C)CSC12)C1=NSC(N)=N1.[I-] SNZWLSICAWEWEJ-LDAXPMKESA-O 0.000 description 1
- XSRFAPFORQYPAD-FGQOPWFUSA-O C.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCCCC(NC(=O)OC(C)(C)C)C(N)=O)CSC12)C1=NSC(N)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCCCC(N)C(N)=O)CSC12)C1=NSC(N)=N1.S.[I-] Chemical compound C.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCCCC(NC(=O)OC(C)(C)C)C(N)=O)CSC12)C1=NSC(N)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCCCC(N)C(N)=O)CSC12)C1=NSC(N)=N1.S.[I-] XSRFAPFORQYPAD-FGQOPWFUSA-O 0.000 description 1
- DBGDVHHLHHQPAR-UHFFFAOYSA-N C.CCOC(=O)CN1C=NC2=C1C=CC=N2.NC(=O)CN1C=NC2N=CC=CC21 Chemical compound C.CCOC(=O)CN1C=NC2=C1C=CC=N2.NC(=O)CN1C=NC2N=CC=CC21 DBGDVHHLHHQPAR-UHFFFAOYSA-N 0.000 description 1
- SCYOXDFSSFOFDU-GQFQUYKPSA-O C.CN(C)C(=O)CN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCF)C3=NSC(N)=N3)C2SC1.COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)N(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.[I-] Chemical compound C.CN(C)C(=O)CN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCF)C3=NSC(N)=N3)C2SC1.COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)N(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.[I-] SCYOXDFSSFOFDU-GQFQUYKPSA-O 0.000 description 1
- HIWPSSNONYIJAD-UHFFFAOYSA-N C.CN(C)C(=O)CN1C=NC2N=CC=CC21.CNC Chemical compound C.CN(C)C(=O)CN1C=NC2N=CC=CC21.CNC HIWPSSNONYIJAD-UHFFFAOYSA-N 0.000 description 1
- FVUHMMLDZYDRTA-UHFFFAOYSA-N C.COCC(CN1C=NC2=C1C=CC=N2)NC(=O)OC(C)(C)C.COCC(CN1C=NC2=C1N=CC=C2)NC(=O)OC(C)(C)C.COCC(COS(C)(=O)=O)NC(=O)OC(C)(C)C Chemical compound C.COCC(CN1C=NC2=C1C=CC=N2)NC(=O)OC(C)(C)C.COCC(CN1C=NC2=C1N=CC=C2)NC(=O)OC(C)(C)C.COCC(COS(C)(=O)=O)NC(=O)OC(C)(C)C FVUHMMLDZYDRTA-UHFFFAOYSA-N 0.000 description 1
- OIWNSMFEWRIQLO-UHFFFAOYSA-N C1=CC2=C(N=C1)N=CN2.CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2.CC(C)(C)OC(=O)NCCCN1C=NC2=C1N=CC=C2.CC(C)(C)OC(=O)NCCCOS(C)(=O)=O Chemical compound C1=CC2=C(N=C1)N=CN2.CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2.CC(C)(C)OC(=O)NCCCN1C=NC2=C1N=CC=C2.CC(C)(C)OC(=O)NCCCOS(C)(=O)=O OIWNSMFEWRIQLO-UHFFFAOYSA-N 0.000 description 1
- ARXJAPTWFRVREF-UHFFFAOYSA-N C1=CC2=C(N=C1)N=CN2.CCOC(=O)CI.CCOC(=O)CN1C=NC2=C1C=CC=N2.CCOC(=O)CN1C=NC2=C1N=CC=C2 Chemical compound C1=CC2=C(N=C1)N=CN2.CCOC(=O)CI.CCOC(=O)CN1C=NC2=C1C=CC=N2.CCOC(=O)CN1C=NC2=C1N=CC=C2 ARXJAPTWFRVREF-UHFFFAOYSA-N 0.000 description 1
- JXEHEBGAGXYQQE-UHFFFAOYSA-N C1=CC2=C(N=C1)N=CN2.CN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.CN(CCCN1C=NC2=C1N=CC=C2)C(=O)OC(C)(C)C.CN(CCCOS(C)(=O)=O)C(=O)OC(C)(C)C Chemical compound C1=CC2=C(N=C1)N=CN2.CN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.CN(CCCN1C=NC2=C1N=CC=C2)C(=O)OC(C)(C)C.CN(CCCOS(C)(=O)=O)C(=O)OC(C)(C)C JXEHEBGAGXYQQE-UHFFFAOYSA-N 0.000 description 1
- YIZSJANXSKZCPA-UHFFFAOYSA-N C=CCBr.C=CCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2 Chemical compound C=CCBr.C=CCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2 YIZSJANXSKZCPA-UHFFFAOYSA-N 0.000 description 1
- DWLJUAQBFFRYIC-BXOCCHFQSA-O C=CCN(CCCN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)OCC2=CC=C(OC)C=C2)N2C(=O)C(NC(=O)/C(=N\OCC)C3=NSC(NC(=O)OC(C)(C)C)=N3)C2SC1)C(=O)OC(C)(C)C.C=CCNCCCN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCC)C3=NSC(N)=N3)C2SC1.Cl.[I-] Chemical compound C=CCN(CCCN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)OCC2=CC=C(OC)C=C2)N2C(=O)C(NC(=O)/C(=N\OCC)C3=NSC(NC(=O)OC(C)(C)C)=N3)C2SC1)C(=O)OC(C)(C)C.C=CCNCCCN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCC)C3=NSC(N)=N3)C2SC1.Cl.[I-] DWLJUAQBFFRYIC-BXOCCHFQSA-O 0.000 description 1
- WYUMZDIVESVUSZ-HYEBSWNJSA-N CC(=O)OC(=O)OC(C)(C)C.CN(C)CCCCC/C=N/C1=C(N(CCCN(C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C=CC=N1 Chemical compound CC(=O)OC(=O)OC(C)(C)C.CN(C)CCCCC/C=N/C1=C(N(CCCN(C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C=CC=N1 WYUMZDIVESVUSZ-HYEBSWNJSA-N 0.000 description 1
- ULCFYPDXGRYCGT-UHFFFAOYSA-N CC(C)(C)OC(=O)N(CCCN1C=NC2=C1C=CC=N2)CCN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)N(CCO)CCCN1C=NC2=C1C=CC=N2.O=C(N=NC(=O)N1CCCCC1)N1CCCCC1 Chemical compound CC(C)(C)OC(=O)N(CCCN1C=NC2=C1C=CC=N2)CCN(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)N(CCO)CCCN1C=NC2=C1C=CC=N2.O=C(N=NC(=O)N1CCCCC1)N1CCCCC1 ULCFYPDXGRYCGT-UHFFFAOYSA-N 0.000 description 1
- RNXDGWPZDXIHMC-UHFFFAOYSA-N CC(C)(C)OC(=O)N(CCO)CCCN1C=NC2=C1C=CC=N2.CC[Si](CC)(CC)OCCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.O Chemical compound CC(C)(C)OC(=O)N(CCO)CCCN1C=NC2=C1C=CC=N2.CC[Si](CC)(CC)OCCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.O RNXDGWPZDXIHMC-UHFFFAOYSA-N 0.000 description 1
- ZXMOUAMLYBDARZ-UHFFFAOYSA-N CC(C)(C)OC(=O)NC(CO)CN1C=NC2=C1C=CC=N2 Chemical compound CC(C)(C)OC(=O)NC(CO)CN1C=NC2=C1C=CC=N2 ZXMOUAMLYBDARZ-UHFFFAOYSA-N 0.000 description 1
- KGUFOHCDPBULQD-UHFFFAOYSA-N CC(C)(C)OC(=O)NCC(O)CCN1C=NC2=C1C=CC=N2.CC(CCN1C=NC2=C1C=CC=N2)CNC(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)NCC(O)CCN1C=NC2=C1C=CC=N2.CC(CCN1C=NC2=C1C=CC=N2)CNC(=O)OC(C)(C)C KGUFOHCDPBULQD-UHFFFAOYSA-N 0.000 description 1
- MIJMKCMLBQITOC-UHFFFAOYSA-N CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2.CC[Si](CC)(CC)OCCBr.CC[Si](CC)(CC)OCCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C Chemical compound CC(C)(C)OC(=O)NCCCN1C=NC2=C1C=CC=N2.CC[Si](CC)(CC)OCCBr.CC[Si](CC)(CC)OCCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C MIJMKCMLBQITOC-UHFFFAOYSA-N 0.000 description 1
- UTTNNROLPYVSHF-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCC[n]1c(nccc2)c2nc1)=O Chemical compound CC(C)(C)OC(N(C)CCC[n]1c(nccc2)c2nc1)=O UTTNNROLPYVSHF-UHFFFAOYSA-N 0.000 description 1
- FEBKNDJQRSYOQL-UHFFFAOYSA-N CC(C)(C)OC(N(C)CCC[n]1c2cccnc2nc1)=O Chemical compound CC(C)(C)OC(N(C)CCC[n]1c2cccnc2nc1)=O FEBKNDJQRSYOQL-UHFFFAOYSA-N 0.000 description 1
- BKXCFURFLJFJTA-JXRFQBIHSA-O CC(C)C[N+]1=CC=CC2=C1N=CN2CC(N)=O.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(CI)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(N)=O)CSC12)C1=NSC(N)=N1.[I-] Chemical compound CC(C)C[N+]1=CC=CC2=C1N=CN2CC(N)=O.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(CI)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(N)=O)CSC12)C1=NSC(N)=N1.[I-] BKXCFURFLJFJTA-JXRFQBIHSA-O 0.000 description 1
- XTFHDRTVUPUXPD-DJDSJKLOSA-O CC(C)C[N+]1=CC=CC2=C1N=CN2CC(N)=O.COC1=CC=C(COC(=O)C2=C(CI)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.NC(=O)CN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCF)C3=NSC(N)=N3)C2SC1.[I-] Chemical compound CC(C)C[N+]1=CC=CC2=C1N=CN2CC(N)=O.COC1=CC=C(COC(=O)C2=C(CI)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.NC(=O)CN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCF)C3=NSC(N)=N3)C2SC1.[I-] XTFHDRTVUPUXPD-DJDSJKLOSA-O 0.000 description 1
- IGNGFGXAWDQJGP-UHFFFAOYSA-N CC1CCN(C)C1 Chemical compound CC1CCN(C)C1 IGNGFGXAWDQJGP-UHFFFAOYSA-N 0.000 description 1
- JDZYZXNTMMBZTQ-CZVYBPCSSA-N CCC1=CC=CC=C1.CO.COC1=CC=C(CN(CCCN(C)C(=O)OC(C)(C)C)C2=C(/N=C/CCCCCN(C)C)N=CC=C2)C=C1 Chemical compound CCC1=CC=CC=C1.CO.COC1=CC=C(CN(CCCN(C)C(=O)OC(C)(C)C)C2=C(/N=C/CCCCCN(C)C)N=CC=C2)C=C1 JDZYZXNTMMBZTQ-CZVYBPCSSA-N 0.000 description 1
- JCGRNPRBHMFNHS-UHFFFAOYSA-N CCCCNC1CC1 Chemical compound CCCCNC1CC1 JCGRNPRBHMFNHS-UHFFFAOYSA-N 0.000 description 1
- SLHDGGORWJZRKA-UHFFFAOYSA-N CCN(CCC=O)C(OC(C)(C)C)=O Chemical compound CCN(CCC=O)C(OC(C)(C)C)=O SLHDGGORWJZRKA-UHFFFAOYSA-N 0.000 description 1
- KVOULVTWHADKFL-UHFFFAOYSA-N CCN(CCC[n]1c2cccnc2nc1)C(OC(C)(C)C)=O Chemical compound CCN(CCC[n]1c2cccnc2nc1)C(OC(C)(C)C)=O KVOULVTWHADKFL-UHFFFAOYSA-N 0.000 description 1
- RGWXJNSEKNYETI-SSHUSWAPSA-O CCNCCCN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCC)C3=NSC(N)=N3)C2SC1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCN(CC)C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.Cl.[I-] Chemical compound CCNCCCN1C=NC2=C1C=CC=[N+]2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCC)C3=NSC(N)=N3)C2SC1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCN(CC)C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.Cl.[I-] RGWXJNSEKNYETI-SSHUSWAPSA-O 0.000 description 1
- KMCVJYCIQGFKPE-RLQJAACWSA-O CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(CI)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCN(CCO[Si](CC)(CC)CC)C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCCNCCO)CSC12)C1=NSC(N)=N1.CC[Si](CC)(CC)OCCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(CI)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCN(CCO[Si](CC)(CC)CC)C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCCNCCO)CSC12)C1=NSC(N)=N1.CC[Si](CC)(CC)OCCN(CCCN1C=NC2=C1C=CC=N2)C(=O)OC(C)(C)C.Cl.[I-] KMCVJYCIQGFKPE-RLQJAACWSA-O 0.000 description 1
- PRFMNPFVQUUROS-RFWQZBLVSA-N CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4C3CC[N-](C(=O)OC(C)(C)C)CC3)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4C3CCNCC3)CSC12)C1=NSC(N)=N1.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4C3CC[N-](C(=O)OC(C)(C)C)CC3)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4C3CCNCC3)CSC12)C1=NSC(N)=N1.Cl.[I-] PRFMNPFVQUUROS-RFWQZBLVSA-N 0.000 description 1
- BSMHZDQMQGRFSP-DXCOCTAZSA-N CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCC[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCCN)CSC12)C1=NSC(N)=N1.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCC[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(=O)NCCN)CSC12)C1=NSC(N)=N1.Cl.[I-] BSMHZDQMQGRFSP-DXCOCTAZSA-N 0.000 description 1
- ZQGNKBMKOKADTH-SZGCKFOHSA-N CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(CO)[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(N)CO)CSC12)C1=NSC(N)=N1.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(CO)[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(N)CO)CSC12)C1=NSC(N)=N1.Cl.[I-] ZQGNKBMKOKADTH-SZGCKFOHSA-N 0.000 description 1
- VFDUVHQGUPAYGM-PRLZIVEVSA-N CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(COC)[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(N)COC)CSC12)C1=NSC(N)=N1.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC(COC)[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC(N)COC)CSC12)C1=NSC(N)=N1.Cl.[I-] VFDUVHQGUPAYGM-PRLZIVEVSA-N 0.000 description 1
- XWHTYUQRWXMSKI-IZWXCQLZSA-O CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC3CN(C(=O)OC(C)(C)C)C3)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC3CNC3)CSC12)C1=NSC(N)=N1.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CC3CN(C(=O)OC(C)(C)C)C3)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CC3CNC3)CSC12)C1=NSC(N)=N1.[I-] XWHTYUQRWXMSKI-IZWXCQLZSA-O 0.000 description 1
- LNOKPVDEVHCOCB-PRLZIVEVSA-N CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCC(O)C[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCC(O)CN)CSC12)C1=NSC(N)=N1.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCC(O)C[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCC(O)CN)CSC12)C1=NSC(N)=N1.Cl.[I-] LNOKPVDEVHCOCB-PRLZIVEVSA-N 0.000 description 1
- KUSNGSJLLCSRAG-PRLZIVEVSA-N CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCC[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCCCN)CSC12)C1=NSC(N)=N1.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCC[N-]C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCCCN)CSC12)C1=NSC(N)=N1.Cl.[I-] KUSNGSJLLCSRAG-PRLZIVEVSA-N 0.000 description 1
- JHZOILNLKRUAOB-RYQQNJAYSA-N CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCN(CC[N-](C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCCNCCN)CSC12)C1=NSC(N)=N1.Cl.[I-] Chemical compound CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)OCC3=CC=C(OC)C=C3)=C(C[N+]3=CC=CC4=C3N=CN4CCCN(CC[N-](C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)CSC12)C1=NSC(NC(=O)OC(C)(C)C)=N1.CCO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC4=C3N=CN4CCCNCCN)CSC12)C1=NSC(N)=N1.Cl.[I-] JHZOILNLKRUAOB-RYQQNJAYSA-N 0.000 description 1
- HCHFLYYLSHRTSF-UHFFFAOYSA-N CCOC(=O)CN1C=NC2=C1C=CC=N2.CN.CNC(=O)CN1C=NC2=C1C=CC=N2 Chemical compound CCOC(=O)CN1C=NC2=C1C=CC=N2.CN.CNC(=O)CN1C=NC2=C1C=CC=N2 HCHFLYYLSHRTSF-UHFFFAOYSA-N 0.000 description 1
- SWMRRARPOXBYDC-SAOHPKBSSA-N CC[V].CO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(CN3C=C[N+]4=C3C=CC=N4)CSC12)C1=NSC(N)=N1.Cl Chemical compound CC[V].CO/N=C(\C(=O)NC1C(=O)N2C(C(=O)[O-])=C(CN3C=C[N+]4=C3C=CC=N4)CSC12)C1=NSC(N)=N1.Cl SWMRRARPOXBYDC-SAOHPKBSSA-N 0.000 description 1
- LQEWXCGISYGVLV-SXMBIPSUSA-N CN(C)CCCCC/C=N/C1=C(NCCCN(C)C(=O)OC(C)(C)C)C=CC=N1.COC(OC)N(C)C Chemical compound CN(C)CCCCC/C=N/C1=C(NCCCN(C)C(=O)OC(C)(C)C)C=CC=N1.COC(OC)N(C)C LQEWXCGISYGVLV-SXMBIPSUSA-N 0.000 description 1
- CZQRBPIUNLSOMN-HKWWAQDQSA-M CNCCCN1C=NC2=C1C=CC=N2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCF)C3=NSC(N)=N3)C2SC1.COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC(N(CCCN(C)C(=O)OC(C)(C)C)CC4=CC=C(OC)C=C4)=C3N=CN(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.O=S(=O)(O)O.[I-] Chemical compound CNCCCN1C=NC2=C1C=CC=N2CC1=C(C(=O)[O-])N2C(=O)C(NC(=O)/C(=N\OCF)C3=NSC(N)=N3)C2SC1.COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC(N(CCCN(C)C(=O)OC(C)(C)C)CC4=CC=C(OC)C=C4)=C3N=CN(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.O=S(=O)(O)O.[I-] CZQRBPIUNLSOMN-HKWWAQDQSA-M 0.000 description 1
- LTFXUXOZSAYLJZ-UHFFFAOYSA-N CO/N=C(\NC(=O)C1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=C(N)N3CCO)CSC12)C1=CSC(N)=N1 Chemical compound CO/N=C(\NC(=O)C1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=C(N)N3CCO)CSC12)C1=CSC(N)=N1 LTFXUXOZSAYLJZ-UHFFFAOYSA-N 0.000 description 1
- DPDFQTZUQPDBNB-VTXJOERPSA-N COC1=CC=C(CN(CCCN(C)C(=O)OC(C)(C)C)C2=C(N=CN(C)C)[N+](CC(C)C)=CC=C2)C=C1.COC1=CC=C(COC(=O)C2=C(CI)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(N)=N4)C(=O)N23)C=C1.[I-] Chemical compound COC1=CC=C(CN(CCCN(C)C(=O)OC(C)(C)C)C2=C(N=CN(C)C)[N+](CC(C)C)=CC=C2)C=C1.COC1=CC=C(COC(=O)C2=C(CI)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(N)=N4)C(=O)N23)C=C1.[I-] DPDFQTZUQPDBNB-VTXJOERPSA-N 0.000 description 1
- KEQDTVLSOMUCQM-MVBFOZEESA-O COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC(N(CCCN(C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C3N=CN(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(N)=N4)C(=O)N23)C=C1.[I-] Chemical compound COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC(N(CCCN(C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C3N=CN(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(N)=N4)C(=O)N23)C=C1.[I-] KEQDTVLSOMUCQM-MVBFOZEESA-O 0.000 description 1
- CLYFIWBTOAFUAT-IJMFVSNCSA-O COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC(N(CCCN(C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C3N=CN(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.[I-] Chemical compound COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC(N(CCCN(C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)=C3N=CN(C)C)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.[I-] CLYFIWBTOAFUAT-IJMFVSNCSA-O 0.000 description 1
- WXLYBCYMYRTORS-HIZLMZKLSA-N COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC4=C3N=CN4C3CC[N-](C(=O)OC(C)(C)C)CC3)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.Cl.NC1=NC(/C(=N/OCF)C(=O)NC2C(=O)N3C(C(=O)[O-])=C(C[N+]4=CC=CC5=C4N=CN5C4CCNCC4)CSC23)=NS1.[I-] Chemical compound COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC4=C3N=CN4C3CC[N-](C(=O)OC(C)(C)C)CC3)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.Cl.NC1=NC(/C(=N/OCF)C(=O)NC2C(=O)N3C(C(=O)[O-])=C(C[N+]4=CC=CC5=C4N=CN5C4CCNCC4)CSC23)=NS1.[I-] WXLYBCYMYRTORS-HIZLMZKLSA-N 0.000 description 1
- ZEQWCDYGCNRRME-MYUBFBFHSA-O COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC4=C3N=CN4CC3=CC=CC=N3)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.Cl.NC1=NC(/C(=N/OCF)C(=O)NC2C(=O)N3C(C(=O)[O-])=C(C[N+]4=CC=CC5=C4N=CN5CC4=CC=CC=N4)CSC23)=NS1.[I-] Chemical compound COC1=CC=C(COC(=O)C2=C(C[N+]3=CC=CC4=C3N=CN4CC3=CC=CC=N3)CSC3C(NC(=O)/C(=N\OCF)C4=NSC(NC(=O)OC(C)(C)C)=N4)C(=O)N23)C=C1.Cl.NC1=NC(/C(=N/OCF)C(=O)NC2C(=O)N3C(C(=O)[O-])=C(C[N+]4=CC=CC5=C4N=CN5CC4=CC=CC=N4)CSC23)=NS1.[I-] ZEQWCDYGCNRRME-MYUBFBFHSA-O 0.000 description 1
- MDGSVAYSIKAQNG-UHFFFAOYSA-N Nc1cccnc1NC=O Chemical compound Nc1cccnc1NC=O MDGSVAYSIKAQNG-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N c1nc(nccc2)c2[nH]1 Chemical compound c1nc(nccc2)c2[nH]1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
- C07D501/56—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- R 2 is hydrogen, optionally substituted lower alkyl or optionally substituted cycloalkyl
- a wavy line means syn- or anti-isomerism or a mixture thereof, an ester, a pharmaceutically acceptable salt, a prodrug, or a solvate thereof (herein after may be referred to as compound (I)).
- Lower alkyl includes a straight or branched C1 to C6 alkyl such as methyl, ethyl, n-propyl, i-propyl, t-butyl, n-pentyl, and n-hexyl, and preferred is C1 to C3 alkyl, more preferred is methyl, ethyl or n-propyl.
- halogen examples include F, Cl, Br and I.
- lower alkoxy examples include oxy bonding to lower alkyl, such as methoxy, ethoxy, n-propoxy, i-propoxy, t-butoxy, n-pentyloxy, and n-hexyloxy.
- R 3 may be located at any of the 2- to 4-positions of the pyridinium ring.
- R 3 is preferably hydrogen.
- the N-containing heterocyclic group means an aromatic or non-aromatic heterocyclic group which contains at least one or more N atom(s) and optional O or S atom(s), such as azetidinyl, pyrrolidinyl, piperidinyl, imidazolydinyl, pyrazolidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, morpholinyl, thio morpholinyl, thiazolinyl, oxazolinyl, imidazolinyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isooxazolyl, thiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, imidazolyl, triazolyl, and tetrazolyl.
- Examples of the pharmaceutically acceptable salt of compound (I) include salts formed with inorganic bases, ammonia, organic bases, inorganic acids, organic acids, basic amino acids, halogen ions or the like, and inner salts.
- Examples of the inorganic base include alkali metal (e.g., Na and K) and alkaline earth metal (e.g., Mg).
- Examples of the organic base include procaine, 2-phenylethylbenzylamine, dibenzylethylenediamine, etanolamine, di etanolamine, tris(hydroxymethyl)aminomethane, polyhydroxyalkylamine, and N-methyl glucosamine.
- examples of the prodrug include an acyloxy derivative which is prepared by reacting a hydroxyl group-containing compound with a proper acyl halide or acid anhydride.
- Preferred acyloxy includes —OCOC 2 H 5 , —OCO(t-Bu), —OCOC 15 H 31 , —OCO(m-COONa-Ph), —OCOCH 2 CH 2 COONa, —OCOCH(NH 2 )CH 3 and —OCOCH 2 N(CH 3 ) 2 .
- examples of the prodrug include an amide derivative which is prepared by reacting an amino group-containing compound with a proper halogenated acid or mixed acid anhydride.
- Preferred amides include —NHCO(CH 2 ) 20 CH 3 , —NHCOCH(NH 2 )CH 3 and the like.
- Compound (I) is preferably a compound described in any of above (11) to (18), more preferably a compound (I) wherein X is N; R 1 is amino; R 2 is —CH 2 F; R 3 is hydrogen; R 4 is —(CH 2 ) 3 NHCH 3 ; R 5 is hydrogen; and the wavy line means syn-isomerism or a salt thereof, esp. mono sulfate, for example.
- sulfate crystals are preferred to non-crystals in the light of their stability for pharmaceutical preparation or the like, and more preferred are crystalline hydrates such as 4- to 7- or 8-hydrate of monosulfate, esp. the 4- or 5-hydrate. These crystals are characterized by specific main peaks of the powder X-ray diffractometry.
- Compound (I) can be synthesized by reacting a 7-amino compound of the formula (II):
- solvents used in the reaction include ethers (e.g., dioxane, THF, diethylether, tert-butylmethylether, and diisopropylether), esters (e.g., ethyl formate, ethyl acetate, and n-butyl acetate), halogenated hydrocarbons (e.g., dichloromethane, chloroform, and carbon tetrachloride), hydrocarbons (e.g., n-hexane, benzene, and toluene), amides (e.g., formamide, N,N-dimethylformamide (DMF), N,N-dimethylacetoamide, and N-methylpyrrolidone), ketones (e.g., acetone and methylethylketone), nitryls (e.g., MeCN and propionitryl), dimethylsulfoxide, and water.
- ethers e.g.
- the amount of compound (III) is usually about 1-5 mol, preferably about 1-2 mol, per compound (II) 1 mol.
- the reaction may be carried out at about ⁇ 80 to 80° C., preferably about ⁇ 40 to 50° C.
- Compound (I) shows a broad antibacterial spectrum and so it can be used for preventing or treating mammals (e.g., humans) for various diseases caused by pathogenic microorganisms, such as respiratory tract infection and genito-urinary tract infection.
- mammals e.g., humans
- pathogenic microorganisms such as respiratory tract infection and genito-urinary tract infection.
- the characters of compound (I) include the following points:
- IR (Nujol) cm ⁇ 1 3430, 3209, 1771, 1734, 1713, 1689, 1635, 1613, 1550, 1248, 1156, 1121.
- Tube Cu; Voltage: 40 KV; Current: 40 mA; Scanning: 3.0°/min; Step: 0.02°; Sampling angle: 5°; Termination angle: 40°.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/318,141 US6800621B2 (en) | 1998-11-27 | 2002-12-13 | Imidazo[4,5-b]-pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum activity |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10-336707 | 1998-11-27 | ||
JP33670798 | 1998-11-27 | ||
PCT/JP1999/006562 WO2000032606A1 (fr) | 1998-11-27 | 1999-11-25 | COMPOSÉS DE CÉPHÈME À BASE D'IMIDAZO[4,5-b]PYRIDINIUMMÉTHYLE À LARGE SPECTRE ANTIBACTÉRIEN |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/006562 A-371-Of-International WO2000032606A1 (fr) | 1998-11-27 | 1999-11-25 | COMPOSÉS DE CÉPHÈME À BASE D'IMIDAZO[4,5-b]PYRIDINIUMMÉTHYLE À LARGE SPECTRE ANTIBACTÉRIEN |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/318,141 Division US6800621B2 (en) | 1998-11-27 | 2002-12-13 | Imidazo[4,5-b]-pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US6518263B1 true US6518263B1 (en) | 2003-02-11 |
Family
ID=18301969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/856,712 Expired - Fee Related US6518263B1 (en) | 1998-11-27 | 1999-11-25 | Imidazo[4,5-b]pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum |
US10/318,141 Expired - Fee Related US6800621B2 (en) | 1998-11-27 | 2002-12-13 | Imidazo[4,5-b]-pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum activity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/318,141 Expired - Fee Related US6800621B2 (en) | 1998-11-27 | 2002-12-13 | Imidazo[4,5-b]-pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum activity |
Country Status (23)
Country | Link |
---|---|
US (2) | US6518263B1 (ko) |
EP (1) | EP1134222B1 (ko) |
JP (1) | JP3636663B2 (ko) |
KR (1) | KR100692169B1 (ko) |
CN (1) | CN100436456C (ko) |
AT (1) | ATE293114T1 (ko) |
AU (1) | AU758662B2 (ko) |
BR (1) | BR9915743A (ko) |
CA (1) | CA2350905C (ko) |
CZ (1) | CZ20011719A3 (ko) |
DE (1) | DE69924751T2 (ko) |
ES (1) | ES2241374T3 (ko) |
HU (1) | HUP0200450A3 (ko) |
ID (1) | ID28740A (ko) |
IL (1) | IL143314A0 (ko) |
NO (1) | NO20012554L (ko) |
NZ (1) | NZ511619A (ko) |
PL (1) | PL347897A1 (ko) |
RU (1) | RU2223964C2 (ko) |
TR (1) | TR200101507T2 (ko) |
TW (1) | TW526202B (ko) |
WO (1) | WO2000032606A1 (ko) |
ZA (1) | ZA200103850B (ko) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052890A1 (en) | 2002-12-06 | 2004-06-24 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
US20040157821A1 (en) * | 2001-04-23 | 2004-08-12 | Hikaru Itani | Sulfate of cephem compound |
US6800621B2 (en) * | 1998-11-27 | 2004-10-05 | Shionogi & Co., Ltd. | Imidazo[4,5-b]-pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum activity |
US20060142265A1 (en) * | 2003-03-17 | 2006-06-29 | Affinium Pharmaceuticals, Inc. | Compositions comprising multiple bioactive agents, and methods of using the same |
WO2008009122A1 (en) | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
US20090042920A1 (en) * | 2002-03-13 | 2009-02-12 | Kristof Van Emelen | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
US20090042927A1 (en) * | 2007-02-16 | 2009-02-12 | PAULS Henry | Salts, Prodrugs and Polymorphs of Fab I Inhibitors |
US20090156578A1 (en) * | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
US20090221699A1 (en) * | 2001-04-06 | 2009-09-03 | Burgess Walter J | Fab I Inhibitors |
US20100093705A1 (en) * | 2004-06-04 | 2010-04-15 | Sargent Bruce J | Therapeutic agents, and methods of making and using the same |
US7790716B2 (en) | 1999-10-08 | 2010-09-07 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
US8901105B2 (en) | 2012-06-19 | 2014-12-02 | Debiopharm International Sa | Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
US8968753B2 (en) | 2013-03-15 | 2015-03-03 | Calixa Therapeutics, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
US9044485B2 (en) | 2013-03-15 | 2015-06-02 | Calixa Therapeutics, Inc. | Ceftolozane antibiotic compositions |
US9724353B2 (en) | 2011-09-09 | 2017-08-08 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US10751351B2 (en) | 2016-02-26 | 2020-08-25 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003012647A (ja) * | 2000-10-04 | 2003-01-15 | Shionogi & Co Ltd | 2,3−ジアミノピリジンの製造方法 |
JP4416111B2 (ja) * | 2002-02-14 | 2010-02-17 | 塩野義製薬株式会社 | 2,3−ジアミノピリジン誘導体の製造方法 |
AU2003241675A1 (en) * | 2002-06-21 | 2004-01-06 | Shionogi And Co., Ltd. | Medicinal cephem compound composition for injection |
JPWO2004026882A1 (ja) * | 2002-09-20 | 2006-01-19 | 塩野義製薬株式会社 | セフェム剤の製法 |
WO2004039816A1 (ja) * | 2002-10-29 | 2004-05-13 | Shionogi & Co., Ltd. | セフェム化合物の無機酸塩の結晶 |
AU2002952355A0 (en) * | 2002-10-30 | 2002-11-14 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
ATE368042T1 (de) * | 2002-10-30 | 2007-08-15 | Astellas Pharma Inc | Cephemverbindungen |
AU2003902380A0 (en) * | 2003-05-16 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
WO2005027909A1 (en) * | 2003-09-18 | 2005-03-31 | Astellas Pharma Inc. | Cephem compounds |
JP4535366B2 (ja) * | 2003-12-03 | 2010-09-01 | 塩野義製薬株式会社 | セフェム剤の製造方法 |
KR20060135796A (ko) * | 2004-03-05 | 2006-12-29 | 시오노기세이야쿠가부시키가이샤 | 3-피리디늄 메틸세펨 화합물 |
JP2006206529A (ja) * | 2005-01-31 | 2006-08-10 | Shionogi & Co Ltd | N−(4−ピリジル)エチレンジアミン誘導体 |
US8198434B2 (en) * | 2008-05-07 | 2012-06-12 | Idexx Laboratories, Inc. | Process for preparing cefsulodin sodium |
CN102443017B (zh) * | 2010-10-13 | 2014-10-29 | 石药集团中奇制药技术(石家庄)有限公司 | 一种盐酸头孢唑兰的制备方法 |
ES2719776T3 (es) | 2012-10-12 | 2019-07-16 | Broad Inst Inc | Inhibidores de GSK3 y métodos de uso de los mismos |
CN107787324B (zh) * | 2015-06-29 | 2020-05-19 | 桑多斯股份公司 | 氨甲酰基氨基吡唑衍生物的制备方法 |
EP3386977A4 (en) * | 2015-12-10 | 2019-05-22 | NAEJA-RGM Pharmaceuticals ULC | CEPHEM COMPOUNDS, THEIR PREPARATION AND USE |
SG11201909115WA (en) | 2017-04-05 | 2019-10-30 | Broad Inst Inc | Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof |
Citations (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3585199A (en) | 1967-05-25 | 1971-06-15 | Merck & Co Inc | (4-(3-(polyazaheterocyclic)alkanoyl)phenoxy)alkanoic acids |
US4002623A (en) | 1974-08-07 | 1977-01-11 | Pfizer Inc. | Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines |
EP0042154A1 (en) | 1980-06-18 | 1981-12-23 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds and processes for preparation thereof |
EP0062321A2 (en) | 1981-04-03 | 1982-10-13 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and their starting compounds |
EP0074268A2 (en) | 1981-09-08 | 1983-03-16 | Eli Lilly And Company | Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives |
US4406899A (en) | 1982-03-04 | 1983-09-27 | Bristol-Myers Company | Cephalosporins |
EP0137441A2 (de) | 1983-10-08 | 1985-04-17 | Hoechst Aktiengesellschaft | Cephalosporinderivate und Verfahren zu ihrer Herstellung |
EP0137440A2 (de) | 1983-10-08 | 1985-04-17 | Hoechst Aktiengesellschaft | Cephalosporinderivate und Verfahren zu ihrer Herstellung |
EP0138552A2 (en) | 1983-10-17 | 1985-04-24 | Eli Lilly And Company | Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins |
US4525473A (en) | 1983-03-30 | 1985-06-25 | Bristol-Myers Company | Cephalosporins |
JPS60120889A (ja) | 1983-11-30 | 1985-06-28 | Meiji Seika Kaisha Ltd | 新規セファロスポリン化合物及びその製造法 |
US4547573A (en) | 1983-12-02 | 1985-10-15 | Ici Pharma | Process for preparing cephalosporin derivatives |
EP0160252A2 (en) | 1984-04-23 | 1985-11-06 | Takeda Chemical Industries, Ltd. | Antibacterial compounds |
US4590186A (en) | 1984-01-16 | 1986-05-20 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds having 3-bicyclic heterocyclic cation groups |
US4609653A (en) | 1982-12-28 | 1986-09-02 | Hoechst Aktiengesellschaft | Crystalline cephem-acid addition salts and processes for their preparation |
EP0203271A2 (en) | 1985-03-01 | 1986-12-03 | Takeda Chemical Industries, Ltd. | Antibacterial compounds, their production and use |
US4748171A (en) | 1985-01-14 | 1988-05-31 | Eisai Co., Ltd. | Cephem compounds having at the 3-position a (1,4-methylene-1-piperidinio)methyl group or a (1-quinuclidinio)methyl group |
US4804658A (en) | 1986-09-15 | 1989-02-14 | G. D. Searle & Co. | Imidazopyridine derivatives and pharmaceutical compositions |
US4864022A (en) | 1985-04-17 | 1989-09-05 | Takeda Chemical Industries, Ltd. | 3-Condensed imidazolium-cephem compounds |
JPH0248587A (ja) | 1988-08-10 | 1990-02-19 | Yamanouchi Pharmaceut Co Ltd | 複素環置換ビスフォスフォン酸誘導体及びその医薬 |
EP0434038A1 (en) | 1989-12-22 | 1991-06-26 | Takeda Chemical Industries, Ltd. | Fused imidazole derivatives, their production and use |
WO1991013070A1 (de) | 1990-02-26 | 1991-09-05 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
WO1992006086A1 (en) | 1990-10-01 | 1992-04-16 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
JPH05201991A (ja) | 1991-07-10 | 1993-08-10 | Dainippon Pharmaceut Co Ltd | アミノ酸誘導体 |
JPH05222058A (ja) | 1992-02-17 | 1993-08-31 | Fujisawa Pharmaceut Co Ltd | 新規セフェム化合物およびその塩 |
JPH05331149A (ja) | 1992-06-02 | 1993-12-14 | Eisai Co Ltd | フェノール誘導体 |
US5281589A (en) | 1991-06-15 | 1994-01-25 | Cheil Foods & Chemicals, Inc. | 3-fused pyridiniummethyl cephalosporins |
JPH0641149A (ja) | 1992-05-28 | 1994-02-15 | Toyama Chem Co Ltd | 新規なセファロスポリン誘導体およびその塩 |
JPH06157542A (ja) | 1992-07-31 | 1994-06-03 | Fujisawa Pharmaceut Co Ltd | 新規セフェム化合物 |
US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
US5334598A (en) | 1993-03-19 | 1994-08-02 | Merck & Co., Inc. | Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives |
WO1994022859A1 (de) | 1993-03-26 | 1994-10-13 | Bayer Aktiengesellschaft | Substituierte, heteroanellierte imidazole und ihre verwendung als herbizide |
US5382586A (en) | 1991-01-28 | 1995-01-17 | Laboratorios Del Dr. Esteve S.A. | Aryl (or heteroaryl)piperazinylalkylazole derivatives, their preparation and their application as medicaments |
US5389634A (en) | 1990-06-08 | 1995-02-14 | Roussel-Uclaf | Imidazole derivatives having angiotensin II receptor antagonistic activity |
JPH07101960A (ja) | 1993-10-05 | 1995-04-18 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
JPH07101958A (ja) | 1992-10-16 | 1995-04-18 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5506238A (en) | 1989-09-29 | 1996-04-09 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
US5635485A (en) | 1994-05-03 | 1997-06-03 | Roussel Uclaf | Erythromycin compounds |
US5635514A (en) | 1994-10-25 | 1997-06-03 | G. D. Searle & Company | Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors |
JPH09165371A (ja) | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
WO1997041128A1 (en) | 1996-04-30 | 1997-11-06 | Fujisawa Pharmaceutical Co., Ltd. | 3-pyrazoliomethylcephem compounds as antimicrobial agents |
US5719306A (en) | 1994-10-11 | 1998-02-17 | G.D. Searle & Co. | LTA4 hydrolase inhibitors |
US5739147A (en) | 1994-05-10 | 1998-04-14 | Hoechst Aktiengesellschaft | Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases |
US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
EP0934941A1 (en) | 1996-08-09 | 1999-08-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA838864B (en) * | 1982-12-17 | 1984-11-28 | Ici Pharma | Process for the manufacture of cephalosporin derivatives |
US4692443A (en) * | 1983-10-17 | 1987-09-08 | Eli Lilly And Company | 3-bicyclicpyridinium-methyl cephalosporins |
GB8712747D0 (en) * | 1987-05-30 | 1987-07-01 | Pfizer Ltd | Therapeutic agents |
JPH02286679A (ja) * | 1989-04-28 | 1990-11-26 | Grelan Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
IL94390A (en) * | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
JPH09110877A (ja) * | 1995-10-17 | 1997-04-28 | Katayama Seiyakushiyo:Kk | セフェム化合物、その製造法及びそれを含有する抗菌剤 |
FR2742052B1 (fr) * | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
TW526202B (en) * | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
-
1999
- 1999-11-24 TW TW088120521A patent/TW526202B/zh not_active IP Right Cessation
- 1999-11-25 AT AT99973033T patent/ATE293114T1/de not_active IP Right Cessation
- 1999-11-25 EP EP99973033A patent/EP1134222B1/en not_active Expired - Lifetime
- 1999-11-25 US US09/856,712 patent/US6518263B1/en not_active Expired - Fee Related
- 1999-11-25 ES ES99973033T patent/ES2241374T3/es not_active Expired - Lifetime
- 1999-11-25 DE DE69924751T patent/DE69924751T2/de not_active Expired - Lifetime
- 1999-11-25 ID IDW00200100967A patent/ID28740A/id unknown
- 1999-11-25 KR KR1020017006658A patent/KR100692169B1/ko not_active IP Right Cessation
- 1999-11-25 JP JP2000585247A patent/JP3636663B2/ja not_active Expired - Fee Related
- 1999-11-25 CN CNB99815816XA patent/CN100436456C/zh not_active Expired - Fee Related
- 1999-11-25 BR BR9915743-8A patent/BR9915743A/pt not_active IP Right Cessation
- 1999-11-25 TR TR2001/01507T patent/TR200101507T2/xx unknown
- 1999-11-25 CZ CZ20011719A patent/CZ20011719A3/cs unknown
- 1999-11-25 CA CA002350905A patent/CA2350905C/en not_active Expired - Fee Related
- 1999-11-25 HU HU0200450A patent/HUP0200450A3/hu unknown
- 1999-11-25 PL PL99347897A patent/PL347897A1/xx not_active Application Discontinuation
- 1999-11-25 WO PCT/JP1999/006562 patent/WO2000032606A1/ja not_active Application Discontinuation
- 1999-11-25 RU RU2001117519/04A patent/RU2223964C2/ru not_active IP Right Cessation
- 1999-11-25 IL IL14331499A patent/IL143314A0/xx unknown
- 1999-11-25 NZ NZ511619A patent/NZ511619A/xx unknown
- 1999-11-25 AU AU14090/00A patent/AU758662B2/en not_active Ceased
-
2001
- 2001-05-11 ZA ZA200103850A patent/ZA200103850B/en unknown
- 2001-05-23 NO NO20012554A patent/NO20012554L/no not_active Application Discontinuation
-
2002
- 2002-12-13 US US10/318,141 patent/US6800621B2/en not_active Expired - Fee Related
Patent Citations (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3585199A (en) | 1967-05-25 | 1971-06-15 | Merck & Co Inc | (4-(3-(polyazaheterocyclic)alkanoyl)phenoxy)alkanoic acids |
US4002623A (en) | 1974-08-07 | 1977-01-11 | Pfizer Inc. | Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines |
EP0042154A1 (en) | 1980-06-18 | 1981-12-23 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds and processes for preparation thereof |
EP0062321A2 (en) | 1981-04-03 | 1982-10-13 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds, processes for their preparation, pharmaceutical compositions containing them and their starting compounds |
EP0074268A2 (en) | 1981-09-08 | 1983-03-16 | Eli Lilly And Company | Improvements in or relating to thieno and furopyridinium-substituted cephalosporin derivatives |
US4406899A (en) | 1982-03-04 | 1983-09-27 | Bristol-Myers Company | Cephalosporins |
US4609653A (en) | 1982-12-28 | 1986-09-02 | Hoechst Aktiengesellschaft | Crystalline cephem-acid addition salts and processes for their preparation |
US4525473A (en) | 1983-03-30 | 1985-06-25 | Bristol-Myers Company | Cephalosporins |
EP0137440A2 (de) | 1983-10-08 | 1985-04-17 | Hoechst Aktiengesellschaft | Cephalosporinderivate und Verfahren zu ihrer Herstellung |
EP0137441A2 (de) | 1983-10-08 | 1985-04-17 | Hoechst Aktiengesellschaft | Cephalosporinderivate und Verfahren zu ihrer Herstellung |
EP0138552A2 (en) | 1983-10-17 | 1985-04-24 | Eli Lilly And Company | Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins |
JPS60120889A (ja) | 1983-11-30 | 1985-06-28 | Meiji Seika Kaisha Ltd | 新規セファロスポリン化合物及びその製造法 |
US4547573A (en) | 1983-12-02 | 1985-10-15 | Ici Pharma | Process for preparing cephalosporin derivatives |
US4590186A (en) | 1984-01-16 | 1986-05-20 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds having 3-bicyclic heterocyclic cation groups |
EP0160252A2 (en) | 1984-04-23 | 1985-11-06 | Takeda Chemical Industries, Ltd. | Antibacterial compounds |
US4748171A (en) | 1985-01-14 | 1988-05-31 | Eisai Co., Ltd. | Cephem compounds having at the 3-position a (1,4-methylene-1-piperidinio)methyl group or a (1-quinuclidinio)methyl group |
EP0203271A2 (en) | 1985-03-01 | 1986-12-03 | Takeda Chemical Industries, Ltd. | Antibacterial compounds, their production and use |
US4864022A (en) | 1985-04-17 | 1989-09-05 | Takeda Chemical Industries, Ltd. | 3-Condensed imidazolium-cephem compounds |
US4804658A (en) | 1986-09-15 | 1989-02-14 | G. D. Searle & Co. | Imidazopyridine derivatives and pharmaceutical compositions |
JPH0248587A (ja) | 1988-08-10 | 1990-02-19 | Yamanouchi Pharmaceut Co Ltd | 複素環置換ビスフォスフォン酸誘導体及びその医薬 |
US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
US5506238A (en) | 1989-09-29 | 1996-04-09 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
EP0434038A1 (en) | 1989-12-22 | 1991-06-26 | Takeda Chemical Industries, Ltd. | Fused imidazole derivatives, their production and use |
WO1991013070A1 (de) | 1990-02-26 | 1991-09-05 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
US5389634A (en) | 1990-06-08 | 1995-02-14 | Roussel-Uclaf | Imidazole derivatives having angiotensin II receptor antagonistic activity |
WO1992006086A1 (en) | 1990-10-01 | 1992-04-16 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
US5382586A (en) | 1991-01-28 | 1995-01-17 | Laboratorios Del Dr. Esteve S.A. | Aryl (or heteroaryl)piperazinylalkylazole derivatives, their preparation and their application as medicaments |
US5281589A (en) | 1991-06-15 | 1994-01-25 | Cheil Foods & Chemicals, Inc. | 3-fused pyridiniummethyl cephalosporins |
JPH05201991A (ja) | 1991-07-10 | 1993-08-10 | Dainippon Pharmaceut Co Ltd | アミノ酸誘導体 |
JPH05222058A (ja) | 1992-02-17 | 1993-08-31 | Fujisawa Pharmaceut Co Ltd | 新規セフェム化合物およびその塩 |
JPH0641149A (ja) | 1992-05-28 | 1994-02-15 | Toyama Chem Co Ltd | 新規なセファロスポリン誘導体およびその塩 |
JPH05331149A (ja) | 1992-06-02 | 1993-12-14 | Eisai Co Ltd | フェノール誘導体 |
JPH06157542A (ja) | 1992-07-31 | 1994-06-03 | Fujisawa Pharmaceut Co Ltd | 新規セフェム化合物 |
JPH07101958A (ja) | 1992-10-16 | 1995-04-18 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
US5334598A (en) | 1993-03-19 | 1994-08-02 | Merck & Co., Inc. | Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives |
WO1994022859A1 (de) | 1993-03-26 | 1994-10-13 | Bayer Aktiengesellschaft | Substituierte, heteroanellierte imidazole und ihre verwendung als herbizide |
JPH07101960A (ja) | 1993-10-05 | 1995-04-18 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5635485A (en) | 1994-05-03 | 1997-06-03 | Roussel Uclaf | Erythromycin compounds |
US6100404A (en) * | 1994-05-03 | 2000-08-08 | Hoechst Marion Roussel | Erythromycin compounds |
US5739147A (en) | 1994-05-10 | 1998-04-14 | Hoechst Aktiengesellschaft | Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases |
US5719306A (en) | 1994-10-11 | 1998-02-17 | G.D. Searle & Co. | LTA4 hydrolase inhibitors |
US5635514A (en) | 1994-10-25 | 1997-06-03 | G. D. Searle & Company | Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors |
US5846990A (en) | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
JPH09165371A (ja) | 1995-10-09 | 1997-06-24 | Sankyo Co Ltd | 複素環化合物を含有する医薬 |
WO1997041128A1 (en) | 1996-04-30 | 1997-11-06 | Fujisawa Pharmaceutical Co., Ltd. | 3-pyrazoliomethylcephem compounds as antimicrobial agents |
EP0934941A1 (en) | 1996-08-09 | 1999-08-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
Non-Patent Citations (1)
Title |
---|
Oak K. Kim et al.: "Synthesis and Structure-Activity Relationship of C-3 Quaternary Ammonium Cephalosporins Exhibiting Anti-MRSA Activities," Biorganic & Medicinal Chemistry Letters, 1997, pp. 2753-2758, vol. 7, No. 21, Elsevier Science Ltd., Pergamon. |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6800621B2 (en) * | 1998-11-27 | 2004-10-05 | Shionogi & Co., Ltd. | Imidazo[4,5-b]-pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum activity |
US8173646B2 (en) | 1999-10-08 | 2012-05-08 | Affinium Pharmaceuticals, Inc. | FAB I inhibitors |
US20110190283A1 (en) * | 1999-10-08 | 2011-08-04 | Miller William H | Fab I Inhibitors |
US7790716B2 (en) | 1999-10-08 | 2010-09-07 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
US7741339B2 (en) | 2001-04-06 | 2010-06-22 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
US8153652B2 (en) | 2001-04-06 | 2012-04-10 | Affinium Pharmaceuticals, Inc. | Fab I inhibitors |
US20110098277A1 (en) * | 2001-04-06 | 2011-04-28 | Burgess Walter J | Fab I Inhibitors |
US20090221699A1 (en) * | 2001-04-06 | 2009-09-03 | Burgess Walter J | Fab I Inhibitors |
US20040157821A1 (en) * | 2001-04-23 | 2004-08-12 | Hikaru Itani | Sulfate of cephem compound |
US20090042920A1 (en) * | 2002-03-13 | 2009-02-12 | Kristof Van Emelen | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
US20060183908A1 (en) * | 2002-12-06 | 2006-08-17 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
WO2004052890A1 (en) | 2002-12-06 | 2004-06-24 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
US7790709B2 (en) | 2002-12-06 | 2010-09-07 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
US7879872B2 (en) | 2003-03-17 | 2011-02-01 | Affinium Pharmaceuticals, Inc. | Compositions comprising multiple bioactive agents, and methods of using the same |
US20060142265A1 (en) * | 2003-03-17 | 2006-06-29 | Affinium Pharmaceuticals, Inc. | Compositions comprising multiple bioactive agents, and methods of using the same |
US20100093705A1 (en) * | 2004-06-04 | 2010-04-15 | Sargent Bruce J | Therapeutic agents, and methods of making and using the same |
US8450307B2 (en) | 2004-06-04 | 2013-05-28 | Affinium Pharmaceuticals, Inc. | Therapeutic agents, and methods of making and using the same |
EP2848614A2 (en) | 2004-06-04 | 2015-03-18 | Debiopharm International SA | Acrylamide derivatives as antibiotic agents |
US20090156578A1 (en) * | 2005-12-05 | 2009-06-18 | PAULS Henry | 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents |
US20100130470A1 (en) * | 2006-07-20 | 2010-05-27 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
WO2008009122A1 (en) | 2006-07-20 | 2008-01-24 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab i inhibitors |
US8318720B2 (en) | 2006-07-20 | 2012-11-27 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as Fab I inhibitors |
EP2687533A2 (en) | 2006-07-20 | 2014-01-22 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as FAB I inhibitors |
US8895545B2 (en) | 2006-07-20 | 2014-11-25 | Debiopharm International Sa | Acrylamide derivatives as Fab I inhibitors |
US20090042927A1 (en) * | 2007-02-16 | 2009-02-12 | PAULS Henry | Salts, Prodrugs and Polymorphs of Fab I Inhibitors |
US8263613B2 (en) | 2007-02-16 | 2012-09-11 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab I inhibitors |
US9862737B2 (en) | 2007-02-16 | 2018-01-09 | Debiopharm International Sa | Salts, prodrugs and polymorphs of fab I inhibitors |
US10028963B2 (en) | 2011-09-09 | 2018-07-24 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US9724353B2 (en) | 2011-09-09 | 2017-08-08 | Merck Sharp & Dohme Corp. | Methods for treating intrapulmonary infections |
US10035813B2 (en) | 2012-06-19 | 2018-07-31 | Debiopharm International Sa | Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
US8901105B2 (en) | 2012-06-19 | 2014-12-02 | Debiopharm International Sa | Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide |
US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
US8685957B1 (en) | 2012-09-27 | 2014-04-01 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
US9044485B2 (en) | 2013-03-15 | 2015-06-02 | Calixa Therapeutics, Inc. | Ceftolozane antibiotic compositions |
US9320740B2 (en) | 2013-03-15 | 2016-04-26 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
US8968753B2 (en) | 2013-03-15 | 2015-03-03 | Calixa Therapeutics, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10420841B2 (en) | 2013-03-15 | 2019-09-24 | Merck, Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US11278622B2 (en) | 2013-03-15 | 2022-03-22 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US10933053B2 (en) | 2013-09-09 | 2021-03-02 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
US10751351B2 (en) | 2016-02-26 | 2020-08-25 | Debiopharm International S.A. | Medicament for treatment of diabetic foot infections |
Also Published As
Publication number | Publication date |
---|---|
HUP0200450A2 (hu) | 2002-07-29 |
TR200101507T2 (tr) | 2001-09-21 |
DE69924751T2 (de) | 2006-03-09 |
CN1333776A (zh) | 2002-01-30 |
US6800621B2 (en) | 2004-10-05 |
NO20012554L (no) | 2001-07-27 |
EP1134222A1 (en) | 2001-09-19 |
US20030149014A1 (en) | 2003-08-07 |
KR20010086058A (ko) | 2001-09-07 |
ES2241374T3 (es) | 2005-10-16 |
TW526202B (en) | 2003-04-01 |
AU758662B2 (en) | 2003-03-27 |
JP3636663B2 (ja) | 2005-04-06 |
BR9915743A (pt) | 2001-08-21 |
WO2000032606A1 (fr) | 2000-06-08 |
KR100692169B1 (ko) | 2007-03-12 |
EP1134222B1 (en) | 2005-04-13 |
CN100436456C (zh) | 2008-11-26 |
EP1134222A4 (en) | 2003-01-29 |
DE69924751D1 (de) | 2005-05-19 |
CA2350905C (en) | 2007-10-23 |
RU2223964C2 (ru) | 2004-02-20 |
HUP0200450A3 (en) | 2004-04-28 |
ZA200103850B (en) | 2002-05-13 |
AU1409000A (en) | 2000-06-19 |
ID28740A (id) | 2001-06-28 |
CZ20011719A3 (cs) | 2001-12-12 |
NZ511619A (en) | 2002-11-26 |
ATE293114T1 (de) | 2005-04-15 |
IL143314A0 (en) | 2002-04-21 |
CA2350905A1 (en) | 2000-06-08 |
PL347897A1 (en) | 2002-04-22 |
NO20012554D0 (no) | 2001-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6518263B1 (en) | Imidazo[4,5-b]pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum | |
US6458950B1 (en) | Compounds and pharmaceutical compositions containing the same | |
EP1489084A1 (en) | Broad-spectrum cephem compounds | |
CZ405797A3 (cs) | Derivát cefalosporinu, způsob jeho přípravy a jeho použití a meziprodukt pro jeho přípravu | |
RU2737892C1 (ru) | Гидроксиалкилтиадиазольные производные | |
GB2159818A (en) | Carbapenem intermediates | |
NO170021B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-propenylcefem-derivater | |
AU635118B2 (en) | 2-(substituted pyrrolidinylthio)carbapenem derivatives | |
US5635500A (en) | Cephem compound and pharmaceutical composition containing the compound | |
KR100497942B1 (ko) | 광학활성을 유발하는 7-피롤리딘 치환체를 갖는 광학활성의 퀴놀린 카르복실산 유도체 및 그의 제조방법 | |
EP0278911A1 (de) | Bicyclische beta-Lactam-carbonsäuren | |
DE68919869T2 (de) | Cephalosporinderivate. | |
EP0188781B1 (en) | 1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same | |
MXPA01005231A (es) | Compuestos de cefem que contienen imidazo[4,5-b]-piridiniometilo, que tienen un amplio espectro antibacteriano | |
EP0193858A1 (en) | New 1-oxa-1-dethia-cephalosporin compounds and antibacterial agent comprising the same | |
JP2003183282A (ja) | カルバペネム化合物 | |
KR100264156B1 (ko) | (e)-프로페닐4급암모늄세펨화합물및이의제조방법 | |
WO2000015640A1 (fr) | Composes de carbapenem | |
JPH01279893A (ja) | セフエム化合物 | |
JPH04321688A (ja) | 2−(置換ピロリジニルチオ)カルバペネム誘導体 | |
EP0256990A1 (de) | Pyridinio-Verbindungen | |
WO2004026882A1 (ja) | セフェム剤の製法 | |
WO1993006102A1 (en) | 2-(substituted pyrrolidinylthio) carbapenem derivative | |
KR20050041249A (ko) | 세팔로스포린 유도체의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SHIONOGI & CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NISHITANI, YASUHIRO;ITANI, HIKARU;IRIE, TADASHI;REEL/FRAME:011965/0284 Effective date: 20010418 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20150211 |